Litcius/Paper detail

NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma

Shishir K. Maithel, Jessica M. Keilson, Hop S. Tran Cao, Manali Rupji, Amit Mahipal, Bruce Lin, Milind Javle, Sean P. Cleary, Mehmet Akce, Jeffrey M. Switchenko, Flavio G. Rocha

2023Annals of Surgical Oncology79 citationsDOIOpen Access PDF

Topics & Concepts

MedicineGemcitabineInternal medicineIntrahepatic CholangiocarcinomaNeutropeniaClinical endpointAdverse effectSurgical oncologyOncologyResponse Evaluation Criteria in Solid TumorsNeoadjuvant therapyFebrile neutropeniaCisplatinSurgeryChemotherapyPhases of clinical researchCancerClinical trialBreast cancerCholangiocarcinoma and Gallbladder Cancer StudiesGallbladder and Bile Duct DisordersPancreatic and Hepatic Oncology Research
NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma | Litcius